$BEAM
Beam Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024121104 Filed on November 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $14.27M
YoY Change -17.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $26.52M
YoY Change 4.35%
% of Gross Profit
Research & Development $94.26M
YoY Change -5.79%
% of Gross Profit
Depreciation & Amortization $5.475M
YoY Change 5.55%
% of Gross Profit
Operating Expenses $120.8M
YoY Change -3.74%
Operating Profit -$106.5M
YoY Change -1.63%
Interest Expense $9.863M
YoY Change 59.6%
% of Operating Profit
Other Income/Expense, Net $9.836M
YoY Change -19.24%
Pretax Income -$96.67M
YoY Change 0.6%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$96.67M
YoY Change 0.6%
Net Earnings / Revenue -677.47%
Basic Earnings Per Share -$1.17
Diluted Earnings Per Share -$1.17
COMMON SHARES
Basic Shares Outstanding 82.81M 82.42M
Diluted Shares Outstanding 82.41M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $925.8M
YoY Change -8.84%
Cash & Equivalents $230.2M
Short-Term Investments $695.6M
Other Short-Term Assets $19.78M
YoY Change -17.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $945.5M
YoY Change -9.04%
LONG-TERM ASSETS
Property, Plant & Equipment $113.5M
YoY Change -10.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.078M
YoY Change -59.35%
Total Long-Term Assets $225.8M
YoY Change -10.02%
TOTAL ASSETS
Total Short-Term Assets $945.5M
Total Long-Term Assets $225.8M
Total Assets $1.171B
YoY Change -9.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.812M
YoY Change 19.99%
Accrued Expenses $64.71M
YoY Change 20.49%
Deferred Revenue $89.33M
YoY Change -41.8%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $166.2M
YoY Change -24.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $481.0K
YoY Change -54.1%
Total Long-Term Liabilities $481.0K
YoY Change -54.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $166.2M
Total Long-Term Liabilities $481.0K
Total Liabilities $380.1M
YoY Change -25.71%
SHAREHOLDERS EQUITY
Retained Earnings -$1.500B
YoY Change 15.38%
Common Stock $826.0K
YoY Change 4.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $791.3M
YoY Change
Total Liabilities & Shareholders Equity $1.171B
YoY Change -9.23%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$96.67M
YoY Change 0.6%
Depreciation, Depletion And Amortization $5.475M
YoY Change 5.55%
Cash From Operating Activities -$88.12M
YoY Change -1.87%
INVESTING ACTIVITIES
Capital Expenditures $1.577M
YoY Change -80.04%
Acquisitions
YoY Change
Other Investing Activities $26.28M
YoY Change -1242.39%
Cash From Investing Activities $24.70M
YoY Change -339.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.262M
YoY Change -96.56%
NET CHANGE
Cash From Operating Activities -88.12M
Cash From Investing Activities 24.70M
Cash From Financing Activities 1.262M
Net Change In Cash -62.16M
YoY Change -1.95%
FREE CASH FLOW
Cash From Operating Activities -$88.12M
Capital Expenditures $1.577M
Free Cash Flow -$89.70M
YoY Change -8.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001745999
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39208
dei Entity Registrant Name
EntityRegistrantName
Beam Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5238376
dei Entity Address Address Line1
EntityAddressAddressLine1
238 Main Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
327-8775
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
BEAM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
816000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2265009000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2169798000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1759000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1171367000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1459714000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14269000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33451000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61517000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94258000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100050000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266117000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25410000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
82865000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73556000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
120773000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
125460000
us-gaap Operating Expenses
OperatingExpenses
348982000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-106504000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-108267000
us-gaap Operating Income Loss
OperatingIncomeLoss
-315531000
us-gaap Operating Income Loss
OperatingIncomeLoss
-309343000
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-200000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4700000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2064000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
CY2024Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
27000
CY2023Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-6002000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1619000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
CY2024Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12127000
CY2023Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12698000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
38166000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
34612000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9836000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12179000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29182000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82805627
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230203000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
435895000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
695554000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
753981000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19777000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21167000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
945534000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1211043000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113502000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124960000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6549000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8719000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
104704000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
112846000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1078000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2146000
CY2024Q3 us-gaap Assets
Assets
1171367000
CY2023Q4 us-gaap Assets
Assets
1459714000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3812000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1617000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
51769000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111664000
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8400000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10800000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
89327000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
68706000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12936000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12778000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
166244000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
205565000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
149129000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
159911000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1104000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2723000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
57816000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
109888000
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5276000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
481000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
298000
CY2024Q3 us-gaap Liabilities
Liabilities
380050000
CY2023Q4 us-gaap Liabilities
Liabilities
478385000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82558883
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82558883
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81632496
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81632496
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
826000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
816000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2265009000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2169798000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1759000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
604000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1476277000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1189889000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
791317000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
981329000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1171367000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1459714000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14269000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17193000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33451000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61517000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94258000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100050000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266117000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26515000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25410000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
82865000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73556000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
120773000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
125460000
us-gaap Operating Expenses
OperatingExpenses
370860000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-106504000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-108267000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81632496
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
826000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2265009000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2169798000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1759000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1476277000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1189889000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
791317000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
981329000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1459714000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14269000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17193000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33451000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61517000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94258000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100050000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266117000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
297304000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26515000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25410000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
82865000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73556000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
120773000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
125460000
us-gaap Operating Expenses
OperatingExpenses
348982000
us-gaap Operating Expenses
OperatingExpenses
370860000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-106504000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-108267000
us-gaap Operating Income Loss
OperatingIncomeLoss
-315531000
us-gaap Operating Income Loss
OperatingIncomeLoss
-309343000
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-200000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4700000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2064000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
CY2024Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
27000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1619000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
CY2024Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12127000
CY2023Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12698000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
38166000
us-gaap Operating Income Loss
OperatingIncomeLoss
-315531000
us-gaap Operating Income Loss
OperatingIncomeLoss
-309343000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4700000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2064000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
CY2024Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
27000
CY2023Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-6002000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1619000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
CY2024Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12127000
CY2023Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12698000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
38166000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
34612000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9836000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12179000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29182000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34019000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96668000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96088000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-286349000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-275324000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-96668000
us-gaap Net Income Loss
NetIncomeLoss
-286388000
us-gaap Net Income Loss
NetIncomeLoss
-275324000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2869000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1155000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
406000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93799000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96097000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-285233000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-274918000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82410095
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82410095
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
34612000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9836000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12179000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29182000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34019000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96668000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96088000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-286349000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-275324000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-96668000
us-gaap Net Income Loss
NetIncomeLoss
-286388000
us-gaap Net Income Loss
NetIncomeLoss
-275324000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2869000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
406000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93799000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96097000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-285233000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-274918000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82410095
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82410095
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79024647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82141383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82141383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
733474000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1708000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23917000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1665000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-96460000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
761506000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26278000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1250000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-82776000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96668000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96088000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-286349000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-275324000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-96668000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-96088000
us-gaap Net Income Loss
NetIncomeLoss
-286388000
us-gaap Net Income Loss
NetIncomeLoss
-275324000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2869000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
406000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93799000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96097000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-285233000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-274918000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.49
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79024647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82141383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82141383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
733474000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1708000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23917000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1665000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-96460000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
761506000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26278000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1250000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-82776000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
811643000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1324000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25835000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778941000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
981329000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1398000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29281000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1676000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1525000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-98669000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
733474000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1708000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23917000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1665000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-96460000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
761506000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26278000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1250000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-82776000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
811643000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1324000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25835000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1292000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-96088000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778941000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1398000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29281000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1676000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1525000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-98669000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
913490000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31604000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-189000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-91051000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
854094000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1224000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29559000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
239000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2869000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-96668000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
791317000
us-gaap Profit Loss
ProfitLoss
-286388000
us-gaap Profit Loss
ProfitLoss
-275324000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16482000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14650000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
18125000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
22389000
us-gaap Share Based Compensation
ShareBasedCompensation
90444000
us-gaap Share Based Compensation
ShareBasedCompensation
76030000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7193000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7117000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
811643000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1324000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25835000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1292000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-96088000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778941000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
981329000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1398000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29281000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1676000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1525000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-98669000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
913490000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31604000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
854094000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1224000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2869000
us-gaap Profit Loss
ProfitLoss
-275324000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16482000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14650000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
18125000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
22389000
us-gaap Share Based Compensation
ShareBasedCompensation
90444000
us-gaap Share Based Compensation
ShareBasedCompensation
76030000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7193000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7117000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1619000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2458000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10043000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2357000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5810000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-53610000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2738000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9676000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7161000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31451000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-60016000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
451000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
823000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-270881000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
913490000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31604000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-189000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-91051000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
854094000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1224000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
239000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2869000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-96668000
us-gaap Profit Loss
ProfitLoss
-275324000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16482000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14650000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
18125000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
22389000
us-gaap Share Based Compensation
ShareBasedCompensation
90444000
us-gaap Share Based Compensation
ShareBasedCompensation
76030000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7193000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7117000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1619000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2458000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10043000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2357000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5810000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-53610000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2738000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9676000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7161000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31451000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-60016000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
451000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
823000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-270881000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-284268000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5976000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30143000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
486439000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
931066000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
551142000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
934950000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58727000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26259000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1619000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2458000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10043000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2357000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5810000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-53610000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2738000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9676000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7161000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31451000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-60016000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
451000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
823000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-270881000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-284268000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5976000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30143000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
931066000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
551142000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
934950000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58727000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26259000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236568000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2622000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3032000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
631000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
485000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1620000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2155000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5386000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4292000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242735000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-207862000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67792000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444614000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
245521000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236752000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
us-gaap Interest Paid Net
InterestPaidNet
32000
us-gaap Interest Paid Net
InterestPaidNet
140000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
451000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2192000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
-1010000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-284268000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5976000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30143000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
486439000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
931066000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
551142000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
934950000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58727000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26259000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236568000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2622000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3032000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
631000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
485000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1620000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2155000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5386000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4292000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242735000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-207862000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67792000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444614000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
245521000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236752000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
us-gaap Interest Paid Net
InterestPaidNet
32000
us-gaap Interest Paid Net
InterestPaidNet
140000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
451000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2192000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
-1010000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
744000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1500000000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
925800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236568000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2622000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3032000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
631000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
485000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1620000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2155000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5386000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4292000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242735000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-207862000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67792000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444614000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
245521000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236752000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
us-gaap Interest Paid Net
InterestPaidNet
32000
us-gaap Interest Paid Net
InterestPaidNet
140000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
451000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2192000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
-1010000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
744000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1500000000
beam Operating Lease Liabilities Increase Decrease
OperatingLeaseLiabilitiesIncreaseDecrease
744000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1500000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments, settlement payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230203000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169049000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6549000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8680000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236752000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230203000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169049000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6549000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8680000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236752000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
180166000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175142000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66664000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50182000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113502000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124960000
CY2024Q3 us-gaap Depreciation
Depreciation
5475000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230203000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169049000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6549000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8680000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
180166000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175142000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66664000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50182000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113502000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124960000
CY2024Q3 us-gaap Depreciation
Depreciation
5475000
CY2023Q3 us-gaap Depreciation
Depreciation
5187000
us-gaap Depreciation
Depreciation
16482000
us-gaap Depreciation
Depreciation
14650000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
180166000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175142000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66664000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50182000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113502000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124960000
CY2024Q3 us-gaap Depreciation
Depreciation
5475000
CY2023Q3 us-gaap Depreciation
Depreciation
5187000
us-gaap Depreciation
Depreciation
16482000
us-gaap Depreciation
Depreciation
14650000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2064000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
CY2024Q3 beam Settlement Agreement Upfront Payment
SettlementAgreementUpfrontPayment
15000000
CY2024Q3 beam Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.01
CY2024Q3 beam Settlement Agreement Upfront Payment Paid
SettlementAgreementUpfrontPaymentPaid
15000000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
693795000
CY2023Q3 us-gaap Depreciation
Depreciation
5187000
us-gaap Depreciation
Depreciation
16482000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2064000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
CY2024Q3 beam Settlement Agreement Upfront Payment
SettlementAgreementUpfrontPayment
15000000
CY2024Q3 beam Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.01
CY2024Q3 beam Settlement Agreement Upfront Payment Paid
SettlementAgreementUpfrontPaymentPaid
15000000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
693795000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
1772000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
473000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
753981000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2024Q3 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
20652000
CY2023Q4 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
43280000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2064000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-13003000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
CY2024Q3 beam Settlement Agreement Upfront Payment
SettlementAgreementUpfrontPayment
15000000
CY2024Q3 beam Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.01
CY2024Q3 beam Settlement Agreement Upfront Payment Paid
SettlementAgreementUpfrontPaymentPaid
15000000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
693795000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
1772000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
13000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
695554000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
753377000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
1077000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
473000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
753981000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2024Q3 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
20652000
CY2023Q4 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
43280000
CY2024Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
1772000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
753377000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
1077000
CY2023Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
473000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2024Q3 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
20652000
CY2023Q4 beam Accrued Contingent Obligation License Agreement Current
AccruedContingentObligationLicenseAgreementCurrent
43280000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13712000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21774000
CY2023Q4 beam Accrued Research Costs
AccruedResearchCosts
9804000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3551000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3468000
CY2024Q3 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
3073000
CY2023Q4 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
4697000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2575000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111664000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13712000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21774000
CY2024Q3 beam Accrued Research Costs
AccruedResearchCosts
8206000
CY2023Q4 beam Accrued Research Costs
AccruedResearchCosts
9804000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3551000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3468000
CY2024Q3 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
3073000
CY2023Q4 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
4697000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2575000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28641000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
51769000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111664000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29559000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25835000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90444000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76030000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13712000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21774000
CY2024Q3 beam Accrued Research Costs
AccruedResearchCosts
8206000
CY2023Q4 beam Accrued Research Costs
AccruedResearchCosts
9804000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3551000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3468000
CY2024Q3 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
3073000
CY2023Q4 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
4697000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2575000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28641000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111664000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29559000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25835000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90444000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76030000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29559000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25835000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
90444000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76030000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276033
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2436259
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
215842
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
451828
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
47.76
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10044622
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.73
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6139139
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
39.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.05
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276033
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2436259
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
215842
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
451828
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
47.76
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10044622
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.73
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6139139
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
39.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13257988
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10905069
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276033
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2436259
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
215842
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
451828
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
47.76
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10044622
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.73
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6139139
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
39.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13257988
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10905069
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13257988
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96668000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96088000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-275324000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82410095
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82410095
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82141383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82141383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96668000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96088000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-286388000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-275324000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82410095
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82410095
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79024647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82141383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82141383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96668000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96088000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-286388000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-275324000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82410095
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82410095
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79024647
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82141383
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82141383
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0000950170-24-121104-index-headers.html Edgar Link pending
0000950170-24-121104-index.html Edgar Link pending
0000950170-24-121104.txt Edgar Link pending
0000950170-24-121104-xbrl.zip Edgar Link pending
beam-20240930.htm Edgar Link pending
beam-20240930.xsd Edgar Link pending
beam-ex31_1.htm Edgar Link pending
beam-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0000950170-24-121104-index-headers.html Edgar Link pending
0000950170-24-121104-index.html Edgar Link pending
0000950170-24-121104.txt Edgar Link pending
0000950170-24-121104-xbrl.zip Edgar Link pending
beam-20240930.htm Edgar Link pending
beam-20240930.xsd Edgar Link pending
beam-ex31_1.htm Edgar Link pending
beam-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
beam-20240930_htm.xml Edgar Link completed
beam-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable